Abstract 154PD
Background
Incidence of gestational breast cancer (GBC) (during pregnancy, lactation or first year postpartum) ranges from 6-15% of BC in the 20-44 subgroup age. GBC is associated with positive nodes, negative hormonal receptors (HR), triple negative and high grade tumors but little is known at molecular level. We explore specific genomic profiles and clinico-epidemiological features of GBC.
Methods
Expression of 105 genes was assessed in 50 evaluable tumors from 70 GBC Spanish patients using nCounter platform. The following signatures were assessed: 1) Intrinsic subtypes; 2) Proliferation (P) and Risk of Recurrence (ROR) scores; 3) Claudin-low and 4) Chemo-Endocrine Sensitivity Predictor (CESP). Genomic profile and clinico-epidemiological data were compared to equivalent nonGBC cohorts from GEICAM/9906 (n = 293) (NCT00129922), Málaga (n = 96) (Cancer Res, 2016 76; P3 07 15) and Alamo III project (n = 1473).
Results
Out of the 70 patients, 43% were diagnosed during pregnancy and 57% postpartum. The table reports patient and tumor characteristics:
| n (%) | GBC | Alamo III | 9906 | Málaga |
|---|---|---|---|---|
| Mean age at diagnosis | 35 | 37 | 37 | 37 |
| Negative HR | 30 (43) | 330 (24) | 33 (16) | 27 (28) |
| T2-T4 | 51 (76) | 787 (56) | 176 (60) | 84 (92) |
| Grade 3 | 38 (63) | 479 (40) | 121 (44) | 38 (47) |
| Ki67 (≥20%) | 33 (89) | 209 (61) | 46 (22) | 60 (64) |
| Family history of BC | 32 (47) | 296 (25) | - | - |
| Mean age at first partum | 31 | 26 | - | - |
Intrinsic subtypes in GBC were 44% Basal-like, 22% Her2-enriched, 20% Luminal B and 14% Luminal A; no Claudin-low tumors were identified. Basal-like phenotype was enriched (44% vs 14%, p
Conclusions
GBC differential biology is suggested by higher Basal-like and lower Luminal A rates, and absence of Claudin-low phenotype, correlating with worse survival and a more aggressive clinico-pathological profile confirmed by a higher ROR-P high rate and lower CESP score.
Legal entity responsible for the study
GEICAM Spanish Breast Cancer Group
Funding
Sociedad Española de Oncologia Medica (SEOM): Grant “SEOM Buckler”, Fundacion BBVA: Solidarity project: “BBVA Solidarity Territories“ Donations from two Associations of Breast Cancer Patients “Rosae” and “Santa Agueda”
Disclosure
A. Prat: Consulting Fees (advisory boards) Nanostring Technologies. All other authors have declared no conflicts of interest.
Resources from the same session
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort
Presenter: Xavier Pivot
Session: Breast cancer, early
Resources:
Abstract
Presentation
Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population
Presenter: Christopher Hart
Session: Breast cancer, early
Resources:
Abstract
Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer
Presenter: Alberto Ocana Fernandez
Session: Breast cancer, early
Resources:
Abstract
Presentation
Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)
Presenter: Luisa Carbognin
Session: Breast cancer, early
Resources:
Abstract
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study
Presenter: Antonino Musolino
Session: Breast cancer, early
Resources:
Abstract
Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)
Presenter: Steven Shak
Session: Breast cancer, early
Resources:
Abstract
Presentation
Invited discussant LBA13 and abstract 144O
Presenter: Marco Colleoni
Session: Breast cancer, early
Resources:
Presentation
Invited discussant abstracts 151PD, 152PD, 153PD, 154PD
Presenter: Karen Gelmon
Session: Breast cancer, early
Resources:
Presentation
Webcast
Invited discussant abstracts 145O and 146O
Presenter: Nadia Harbeck
Session: Breast cancer, early
Resources:
Presentation
Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC)
Presenter: Sara Hurvitz
Session: Breast cancer, early
Resources:
Abstract